Cited by 1,047Atrial Fibrillation Management and OutcomesBlood Coagulation and Thrombosis MechanismsVenous Thromboembolism Diagnosis and Management

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity

Open access

Siegal, Deborah M., Curnutte, John T., Connolly, Stuart J., Lu, Genmin, Conley, Pamela B., Wiens, Brian L., Mathur, Vandana S., Castillo, Janice, Bronson, Michele D., Leeds, Janet M., Mar, Florie A., Gold, Alex, Crowther, Mark A.·2015·New England Journal of Medicine

DOI 10.1056/nejmoa1510991

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Bleeding is a complication of treatment with factor Xa inhibitors, but there are no specific agents for the reversal of the effects of these drugs. Andexanet is designed to reverse the anticoagulant effects of factor Xa inhibitors. METHODS: Healthy older volunteers were given 5 mg of apixaban twice daily or 20 mg of rivaroxaban daily. For each factor Xa inhibitor, a two-part randomized placebo-controlled study was conducted to evaluate andexanet administered as a bolus or as a bolus plus a 2-hour infusion. The primary outcome was the mean percent change in anti-factor Xa activity, which is a measure of factor Xa inhibition by the anticoagulant. RESULTS: Among the apixaban-treated participants, anti-factor Xa activity was reduced by 94% among those who received an andexanet bolus (24 participants), as compared with 21% among those who received placebo (9 participants) (P<0.001), and unbound apixaban concentration was reduced by 9.3 ng per milliliter versus 1.9 ng per milliliter (P<0.001); thrombin generation was fully restored in 100% versus 11% of the participants (P<0.001) within 2 to 5 minutes. Among the rivaroxaban-treated participants, anti-factor Xa activity was reduced by 92% among those who received an andexanet bolus (27 participants), as compared with 18% among those who received placebo (14 participants) (P<0.001), and unbound rivaroxaban concentration was reduced by 23.4 ng per milliliter versus 4.2 ng per milliliter (P<0.001); thrombin generation was fully restored in 96% versus 7% of the participants (P<0.001). These effects were sustained when andexanet was administered as a bolus plus an infusion. In a subgroup of participants, transient increases in levels of d-dimer and prothrombin fragments 1 and 2 were observed, which resolved within 24 to 72 hours. No serious adverse or thrombotic events were reported. CONCLUSIONS: Andexanet reversed the anticoagulant activity of apixaban and rivaroxaban in older healthy participants within minutes after administration and for the duration of infusion, without evidence of clinical toxic effects. (Funded by Portola Pharmaceuticals and others; ANNEXA-A and ANNEXA-R ClinicalTrials.gov numbers, NCT02207725 and NCT02220725.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1510991

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Idarucizumab for Dabigatran Reversal
Pollack, C. V., Reilly, P. A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R. A., Dubiel, R., Huisman, M. V., Hylek, E. M., Kamphuisen, P. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502000 · Cited by 1,552
Idarucizumab for dabigatran reversal
Garrett, A. D., PharmD, & Bcps (2015) · Cited by 1,169
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa
Lu, G., DeGuzman, F. R., Hollenbach, S. J., Karbarz, M. J., Abe, K. Y., Lee, G., Luan, P., Hutchaleelaha, A., Inagaki, M., Conley, P. B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3102 · Cited by 700
Self-citation
Probability Tables for Individual Comparisons by Ranking Methods
Wilcoxon, F. (1947) · Biometrics · doi:10.2307/3001946 · Cited by 578
MicroRNA-328 Contributes to Adverse Electrical Remodeling in Atrial Fibrillation
Lu, Y., Zhang, Y., Wang, N., Pan, Z., Gao, X., Zhang, F., Zhang, Y., Shan, H., Luo, X., Bai, Y., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.958967 · Cited by 450
Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry
Beyer‐Westendorf, J., Förster, K., Pannach, S., Ebertz, F., Gelbricht, V., Thieme, C., Michalski, F., Köhler, C. U., Werth, S., Şahin, K., et al. (2014) · Blood · doi:10.1182/blood-2014-03-563577 · Cited by 408
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) – March 2013
Pernod, G., Albaladejo, P., Godiér, A., Samama, C. M., Susen, S., Gruel, Y., Blais, N., Fontana, P., Cohen, A. A., Llau, J. V., et al. (2013) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2013.04.009 · Cited by 310

Flagged first, then by citations

Show all 22 references

Research works printed but not linked: 1

Crowther MA, 2013, J Thromb Haemost, 11, OC 20.1

Sorted by citations

Items 901–1,000 of 1,000

Reversal of oral anticoagulants
van Ryn, J. (2018) · doi:10.1093/med/9780198784906.003.0058
Perioperatives Management von Patienten mit gerinnungshemmenden Medikamenten in der Wirbelsäulenchirurgie
Gerlach, R., & Lapp, H. (2018) · Die Wirbelsäule · doi:10.1055/s-0043-125077
Reversal of direct oral anticoagulants
Cohen, O. C., Frank, L.-A., & Bradley, S. (2018) · British Journal of Hospital Medicine · doi:10.12968/hmed.2018.79.5.c70
Novel Oral Anticoagulants, A Subject in Continuing Debate
Leon, M. M., Maștaleru, A., Mitu, O., Zota, M., Vasilcu, T. F., Gavril, R. S., & Mitu, F. (2018) · Internal Medicine · doi:10.2478/inmed-2018-0013
[Vaccination schedule for children].
Stickl, H. (1980) · PubMed
For Your Patients-Anticoagulants
Samson, K. (2018) · Neurology Today · doi:10.1097/01.nt.0000542317.68799.7f
Pharmacologic Reversal Agents
Gilmore, J. F., Schontz, M. J., & Lupi, K. E. (2018) · Springer eBooks · doi:10.1007/978-3-319-71240-6_11
Oral Anticoagulation in 2017
Vanassche, T., & de Werf, F. V. (2018) · THE BANGKOK MEDICAL JOURNAL · doi:10.31524/bkkmedj.2018.09.015
Management of Antithrombotic-Related Intracerebral Hemorrhage
Girotra, T., Feng, W., & Ovbiagele, B. I. (2018) · Stroke revisited · doi:10.1007/978-981-10-1427-7_14
Management of Bleeding Associated With Anticoagulation
Merli, G. J., & Thomson, L. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55429-9.00007-8
Role of Blood Bank, Transfusion Services, and Pharmacy in ICU Patients with Hematologic Challenges
Cruz, J. E., Nemeth, J., & Burga, A. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-93572-0_20
Anticoagulants in the ICU
d’Empaire, P. P., Bhuptani, P., Ho, S., & Mazer, C. D. (2018) · Springer eBooks · doi:10.1007/978-3-319-93572-0_17
Recent Advances and Perioperative Management in Platelet and Coagulation
Ogawa, S., & Takeshita, S. (2018) · THE JOURNAL OF JAPAN SOCIETY FOR CLINICAL ANESTHESIA · doi:10.2199/jjsca.38.519
Efeito dos anticoagulantes sobre a agregabilidade plaquetária: ação da heparina de baixo peso molecular enoxaparina, e do inibidor direto da trombina dabigatrana
Arantes, F. B. B. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2018.tde-22102018-135800
Specific treatment of intracerebral hemorrhage
Sato, S., & Anderson, C. S. (2019) · Wiley eBooks · doi:10.1002/9781118492390.ch14
Non-medical prescribing: a reflective case study on prescribing anticoagulation for deep vein thrombosis
Gonet, S. (2019) · Emergency Nurse · doi:10.7748/en.2019.e1897
Rivaroxaban e malattia renale cronica: evidenze dal presente e prospettive future
Lullo, L. D., Ronco, C., Floccari, F., Pascalis, A. D., Bàrbera, V., Rivera, R. F., & Bellasi, A. (2019) · Giornale di Techniche Nefrologiche e Dialitiche · doi:10.1177/0394936219836652
Andexanet Alfa als Antidot für Faktor-Xa-Hemmer
Medizin, S. (2016) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-016-1682-z
Preoperative Management of Oral Anticoagulants
Hansson, E. C., & Jeppsson, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-15342-7_7
WITHDRAWN: Anticoagulant-associated intracerebral hemorrhage
Morotti, A., & Goldstein, J. N. (2019) · Brain Hemorrhages · doi:10.1016/j.hest.2019.06.001
Consideration of Anticoagulation: Surgical Care for the Elderly in Current Geriatrics Reports
Gallaher, J. R., Grudziak, J., & Schreiber, M. A. (2019) · Current Geriatrics Reports · doi:10.1007/s13670-019-00290-w
Prise en charge hémostatique des hémorragies cérébrales sous anticoagulants oraux
Vigué, B., & Samama, C. M. (2019) · Médecine Intensive Réanimation · doi:10.3166/rea-2019-0113
Expanding the Toolbox for Reversal of Anticoagulation in Chronic Kidney Disease
Khedraki, R., Muse, E. D., & Steinhubl, S. R. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.07.073
Anticoagulation in the Hospitalized Patient with Decompensated Cirrhosis: Management of a Delicate Balance
Davis, J. P. E., & Intagliata, N. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-24490-3_12
Consenso sulla diagnostica di laboratorio per i pazienti in trattamento con farmaci anticoagulanti ad azione diretta. Sottoscritto dalla Società Italiana per lo Studio dell'Emostasi e della Trombosi (SISET), dalla Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA), dalla Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica (SIBioC) e dalla Società Italiana di Patologia Clinica e Medicina di Laboratorio (SIPMeL)
Paoletti, O., Legnani, C., Martini, G., Bertini, M., Agostini, P., Bondanini, F., Cozzi, M. R., Demicheli, M. S. A., Felice, G. D., Novembrino, C., et al. (2019) · La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine · doi:10.23736/s1825-859x.19.00009-4
Fall 19 – Abflussstörung
Hübler, A., & Hübler, M. (2019) · Springer eBooks · doi:10.1007/978-3-662-58308-1_19
Coagulation test and anti-factor Xa activity in patients treated with edoxaban
Nishimura, K., Fukushima, T., Fukushima, K., Iida, S., & Kuwabara, S. (2019) · Nosotchu · doi:10.3995/jstroke.10678
Updates on Direct Oral Anticoagulants in the Management of Atrial Fibrillation
Cheng, J. W. M. (2019) · European Journal of Arrhythmia & Electrophysiology · doi:10.17925/ejae.2019.5.1.24
Management of Hemorrhage Related to Direct Action Oral Anticoagulant Medication
Ganem, I. R. A., Martins, L. C. B., & Tomé, C. E. M. (2019) · Journal of Cardiac Arrhythmias · doi:10.24207/jca.v32i2.008_in
Manejo das Hemorragias Relacionadas aos Anticoagulantes Orais de Ação Direta
Ganem, I. R. A., Martins, L. C. B., & Tomé, C. E. M. (2019) · Journal of Cardiac Arrhythmias · doi:10.24207/jca.v32i2.008_pt
Bleeding on Anti-Xa Drugs: “Does All Bleeding Really Stop?”
Kaide, C. G., & Kauffman, K. (2019) · Springer eBooks · doi:10.1007/978-3-030-22445-5_1
What anticoagulants should be used in the critically ill patient? How do I choose?
Hendrix, C. J., Rivas, L., & Sarani, B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-64068-8.00092-4
Management of Periprocedural Anticoagulation
Jain, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-67969-5.00017-4
Oral anticoagulants: Optimizing venous thromboembolism management
Aleidan, F. A. S. (2019) · Journal of Applied Hematology · doi:10.4103/joah.joah_47_19
Controlled Substance Validation
Diaz, C. M., Hernandez, J. F., Neubauer, L. G., & Corrales, E. G. (2020) · Scholarly Commons - Baptist Health South Florida (Baptist Health South Florida)
Efficacy and safety of new direct oral anticoagulants in chronic kidney disease: AHA 2019 updated guidelines and review of the literature
Stȩpak, H., Krasiński, Z., Jawien, A. A., Ahmadi, N., Lipowski, A., & Stanišić, M.-G. (2019) · Polish Journal of Cardio-Thoracic Surgery · doi:10.5114/kitp.2019.91389
Management of antithrombotic therapy in gray areas of venous thromboembolism: a Delphi consensus panel
Barillari, G., Bortoluzzi, C., Giorgi, M., Orabona, R., Pacetti, E., Sciatti, E., Zaffaroni, M., & Dentali, F. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02300-8
Leitsymptom Herzrasen
(2017) · Elsevier eBooks · doi:10.1016/b978-3-437-21105-8.00002-5
Manejo práctico de los nuevos anticoagulantes orales en fibrilación auricular no valvular
Laguado, M., Ardila-Acuña, L. Y., Mayorga-Quintero, J. A., & Rangel-Vera, J. A. (2019) · Medunab · doi:10.29375/01237047.2823
Reversal strategies and outcomes in patients with atrial fibrillation and warfarin-associated intracranial hemorrhage
Singer, D. E., Borowsky, L. H., Regan, S., Lee, J. W., Zint, K., França, L. R., & Goldstein, J. N. (2020) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2020.104903
Os novos anticoagulantes orais na profilaxia de acidente vascular cerebral em pacientes com fibrilação atrial não valvar
Ribeiro, I. N. C., Queiroz, T. S. S., Pires, M. M., & de Jesus, P. A. P. (2020) · Revista Científica Hospital Santa Izabel · doi:10.35753/rchsi.v1i4.162
The Potential of Andexanet Alfa as a Reversal Agent for Direct Oral Anticoagulants
Truong, S., Cong, C., & Weng, R. R. (2020) · Medical Journal of Southern California Clinicians · doi:10.38206/130108
Reversal of Oral Anticoagulants in the Elderly
Jafri, F. M., Batool, S., Dhaduk, K., & Lerner, R. G. (2020) · Springer eBooks · doi:10.1007/978-3-030-47963-3_5
Flipping a Switch: Advances in DOAC Reversal in 2015
Cuker, A. C. (2016) · The Hematologist · doi:10.1182/hem.v13.1.4815
Andexanet alfa reduziert die biologische Aktivität von Faktor-Xa-Hemmern um 90 %
Medizin, S. (2017) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-017-2100-x
Relapsing Urinary Catheter Bleeding with Triple Antithrombotic Therapy in an Elderly Patient with ACS, PCI and A-fib: A Case Report
Naafs, M. A. (2018) · Advancements in Case Studies · doi:10.31031/aics.2018.01.000517
Advances in the Management of Atrial Fibrillation with a Special Focus on Non-Pharmacological Approaches to Prevent Thromboembolism: A Review of Current Recommendations
Riddle, M., McCallum, R. W., Ojha, C. P., Paul, T. K., Gupta, V., Baran, D. A., Prakash, B. V., Misra, A., Mares, A. C., Abedin, M., et al. (2020) · Journal of Investigative Medicine · doi:10.1136/jim-2020-001500
Drugs, Devices, and Procedural Therapies to Prevent Recurrent Cardiogenic Embolic Stroke
Hankey, G. J. (2020) · Cambridge University Press eBooks · doi:10.1017/9781316286234.019
Prospective Randomized Study of the Safety and Efficacy of Interrupted Anticoagulant’s Therapy in the Perioperative Period of Catheter Ablation for Atrial Fibrillation: The SEACOAST Rhythm AF Trial
Watanabe, N., Ogawa, K., Nakamura, Y., INOGUCHI, K., Ochi, A., CHIBA, Y., Oonishi, Y., Kawasaki, S., OONUMA, M., Itou, T., et al. (2020) · The Showa University Journal of Medical Sciences · doi:10.15369/sujms.32.221
Considerations and Guidelines for Use of Anticoagulants and Antithrombotics in Patients Undergoing Interventional Pain Management
Renschler, J. S., Granier, A. L., Jeha, G. M., Scheinuk, J. E., Nungesser, M. E., Etienne, J. M., Erwin, A. P., Cherenfant, C., Umeh, U. O., Webb, M. P., et al. (2021) · Springer eBooks · doi:10.1007/978-3-030-59295-0_47
Manejo das Hemorragias Relacionadas aos Anticoagulantes Orais de Ação Direta: Manejo das Hemorragias Relacionadas aos Anticoagulantes Orais de Ação Direta
Ganem, I. R. A., Martins, L. C. B., & Tomé, C. E. M. (2019) · Journal of Cardiac Arrhythmias
Andexanet Alfa Use for Small Bowel Obstruction Patient With History of Sugiura Procedure
Brust, A., LeCourt, A. P., Benham, D. A., Gower, J. R., & Birmingham, S. D. (2021) · Military Medicine · doi:10.1093/milmed/usab151
Commentary: Moving the Dial on DOAC use Early After Cardiac Surgery
Osho, A. A., & Vlahakes, G. J. (2021) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2021.06.007
Neurochirurgische Intensivmedizin bei älteren Patienten
Bender, M. (2021) · Springer eBooks · doi:10.1007/978-3-662-60354-3_7
Direct Oral Anticoagulant Reversal for Management of Bleeding and Emergent Surgery
Music, S., Eikelboom, J. W., & Huynh, T. T. (2021) · Springer eBooks · doi:10.1007/978-3-030-74462-5_5
Management of the Gastrointestinal System Bleeding Caused by Direct-Acting Oral Anticoagulants
Acar, Ş., & Eminler, A. T. (2021) · Journal of Experimental and Clinical Medicine · doi:10.52142/omujecm.38.si.gastro.4
Anticoagulant therapy in patients with atrial fibrillation: management of bleeding
Zotova, I. V. (2021) · Russian Medicine · doi:10.17816/0869-2106-2021-27-1-57-65
Fatigue in oncology. A marginalized symptom by oncologists, silently handicapping cancer patients!
Laboratoire de chimie thérapeutique, F. D. M. E. D. P. D. R., Fettah, H., Moutaouakkil, Y., Addaoui, A., & Lamsaouri, J. (2019) · Batna Journal of Medical Sciences (BJMS) · doi:10.48087/bjmsra.2019.6104
Commonly Prescribed and Over-the-Counter Drugs as Secondary Causes of Osteoporosis-Part One.
Pizzorno, J. E., & Pizzorno, L. (2021) · PubMed Central
Spontaneous Intracerebral Hemorrhage
Lee, J. S., & Rybinnik, I. (2021) · Neuromethods · doi:10.1007/978-1-0716-1530-0_20
Anticoagulants in Trauma
Greig, R. (2022) · Springer eBooks · doi:10.1007/978-3-030-83628-3_17
Cardiac Arrhythmias
Gutierrez, C., & Hatamy, E. (2022) · Springer eBooks · doi:10.1007/978-3-030-54441-6_84
2 venous thromboembolism (VTE) Venous Thromboembolism
(2020) · Thieme eBooks · doi:10.1055/b-0040-177990
Anticoagulation Reversal
Hornacek, D., & Gomes, M. P. V.-F. (2018) · Springer eBooks · doi:10.1007/978-3-319-73709-6_6
Osteoporosis
Pizzorno, L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-43044-9.00203-x
Prehospital and Emergency Department Care of the Patient With Acute Stroke
Kircher, C. E., & Adeoye, O. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-69424-7.00052-1
Leitsymptom Herzrasen
(2022) · Elsevier eBooks · doi:10.1016/b978-3-437-21115-7.00002-0
Monitoring and Reversal of Anticoagulation and Antiplatelet Agents
Gurbel, P. A., Rout, A., & Tantry, U. S. (2022) · Interventional Cardiology · doi:10.1002/9781119697367.ch46
Antiplatelet and Anticoagulant Agents
Ibrahim, I. F., & Rice, L. (2021) · Springer eBooks · doi:10.1007/978-3-030-56338-7_30
Perioperative management of the high-risk surgical patient: cardiac surgery
Ranucci, M., Castelvecchio, S., & Ballotta, A. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780198849346.003.0076
SCHLAGANFALL
Jung, N., Mayet, W.-J., Mertens, P. R., Meyer, J., Müller, O.-A., Pfeifer, M., Schellinger, P. D., Weiss, N., & Wendtner, C.-M. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-06282-7.50019-x
Rescue Therapies
Glund, S., & Kroez, M. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527699124.ch19
Andexanet Response
Milling, T. J., & Connolly, S. J. (2019) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2019.05.033
Self-citation
Faculty Opinions recommendation of Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis.
Samama, C. M. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734955679.793555939
Leitsymptom Herzrasen
(2020) · Elsevier eBooks · doi:10.1016/b978-3-437-21114-0.00002-5
Intracranial Bleeding
Yasaka, M. (2016) · Springer eBooks · doi:10.1007/978-981-10-1878-7_3
Andexanet for reversal of anticoagulants
(2015) · Reactions Weekly · doi:10.1007/s40278-015-10969-6
Cardiac Arrhythmias
Gutierrez, C., & Hatamy, E. (2020) · Springer eBooks · doi:10.1007/978-1-4939-0779-3_84-2
2015 Hot Topics
(2016) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.27.91
Which Are the Best Techniques for Reducing the Incidence of Postoperative Deep Vein Thrombosis?
Samama, C. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-77846-6.00046-x
Choice of anticoagulant in patients with atrial fibrillation that occurred in the conditions of COVID-19 (clinical case)
Панченко, Е. П. (2022) · Aterotromboz = Atherothrombosis · doi:10.21518/2307-1109-2022-12-1-84-112
Factor Xa inhibitors, Era to replace traditional anticoagulants
Chaudhry, S. (2022) · Journal of Pharmaceutical and Biological Sciences · doi:10.18231/j.jpbs.2022.004
Antithrombotic Reversal Agents
Gupta, N., Chapegadikar, P., & Srivastava, P. (2022) · Springer eBooks · doi:10.1007/978-981-19-0954-2_34
Andexanet alfa
Weiler, S. (2021) · pharma-kritik · doi:10.37667/pk.2021.1174
BLASKI I CIENIE WSPÓŁCZESNEJ FARMAKOTERAPII ANTYKOAGULACYJNEJ
Kałaska, B., Mikłosz, J., Sokołowska, E., & Mogielnicki, A. (2016) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.119
Journal watch
Singh, A. (2016) · Heart India · doi:10.4103/2321-449x.190756
Estudo prospectivo da avaliação do protocolo odontológico para extração dentária em pacientes portadores de fibrilação atrial em uso contínuo dos novos anticoagulantes orais: estudo piloto
Higashi, E. M. (2022) · doi:10.11606/t.5.2022.tde-03102022-134215
Avaliação do diâmetro da bainha do nervo óptico e parâmetros do ultrassom transcraniano como preditores de mortalidade e desfechos clínicos em pacientes com hemorragia intraparenquimatosa cerebral primária aguda
Dias, F. A. (2017) · doi:10.11606/d.17.2017.tde-09112022-113347
Interpreting Findings with Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation: Collective Views on Data from Seminal Studies to Present in Clinical Practice
Mughal, T. (2016) · EMJ Cardiology · doi:10.33590/emjcardiol/10312254
Management of anticoagulant treatment in patients who need non-cardiac surgery
Rostagno, C. (2022) · Vessel Plus · doi:10.20517/2574-1209.2022.09
Hyperacute Medical Management of Intracerebral Haemorrhage
Paterson, A., & Parry‐Jones, A. (2023) · Advances in Clinical Neuroscience & Rehabilitation · doi:10.47795/ziui6736
中和剤の出現による今後の心房細動カテーテルアブレーション周術期の抗凝固療法のありかた
Okishige, K. (2023) · Japanese Journal of Electrocardiology · doi:10.5105/jse.43.44
Top 25 Medications the Plastic and Reconstructive Surgery Trainee Should Know for an Emergency Medicine Department Consult
Azoury, S. C., & Matros, E. (2023) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000010609
Microcirculation - Updates in the Next Frontier of Vascular Disease
Kibel, A., & Firstenberg, M. S. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1001544
Andexanet alfa - what we know about this promising drug
Ilnicka, N., Zuziak, P., Sadlik, M., Matyja, D., & Abod, L. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.16.01.016
Prevention and treatment of bleeding related to antithrombotic drugs
Mehran, R., Spirito, A., Cao, D., & Dangas, G. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780192869227.003.0024
Part I: Interactive case: Life‐threatening bleeding caused by anticoagulants
Owen, E. J. (2023) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1897
Novel Oral Anticoagulants in Cardiovascular Practice
Raza, S. H., Tun, H. N., Cader, F. A., Sabatino, J., & Fatima, M. (2023) · Pakistan Heart Journal · doi:10.47144/phj.v56i4.2618
DOACs for the Medical Management of Venous Thromboembolism in Adults
Kommu, S., & Arepally, S. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.112581
Voyaging to Safety: Anticoagulation in Peripheral Artery Disease and Limb Revascularisation
Shahid, M., Franco, N. F., & Sistla, L. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.112773

Authors: Siegal, D. M., Curnutte, J. T., Connolly, S. J., Lu, G., Conley, P. B., Wiens, B. L., Mathur, V. S., Castillo, J., Bronson, M. D., Leeds, J. M., Mar, F. A., Gold, A., & Crowther, M. A.
Affiliations: Population Health Research Institute (CA)
Portola Pharmaceuticals (United States) (US)
McMaster University (CA)
ORCID: Siegal, Deborah M.
Connolly, Stuart J.
Lu, Genmin
Conley, Pamela B.
Wiens, Brian L.
Mathur, Vandana S.
Crowther, Mark A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2015-12-17
Volume: 373
Issue: 25
Pages: 2413-2424
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1510991
OpenAlex: W2174386486
Cited by: 1,047
References: 22
Citations by year: 2026: 21 · 2025: 34 · 2024: 48 · 2023: 56 · 2022: 44 · 2021: 57 · 2020: 91 · 2019: 126 · 2018: 133 · 2017: 175 · 2016: 249 · 2015: 11
FWCI: 137.31
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords: andexanet alfa, factor Xa inhibitors, apixaban, rivaroxaban, anticoagulant reversal, bleeding complications, anti-Xa activity, thrombin generation, unbound drug concentration, D-dimer, prothrombin fragments, older adults, drug safety, pharmacokinetics, pharmacodynamics, thromboprophylaxis, thrombolysis
MeSH terms: Rivaroxaban, Administration, Oral, Aged, Antidotes, Blood Coagulation, Double-Blind Method, Female, Hemorrhage, Humans, Male, Middle Aged, Peptide Fragments, Protein Precursors, Prothrombin, Pyrazoles, Pyridones, Recombinant Proteins, Factor Xa, Factor Xa Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks